
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics is a medical technology company with significant potential for growth and profitability in the sleep-disordered breathing market. While there is a need for additional financing in the near term, the company has a strong strategic investor and potential for accretive acquisitions to drive growth and improve profitability. Recent financial results have shown strong revenue growth and improved gross margins, although net losses widened due to a transition to a new distribution strategy. The company's recent partnership with SoundHealth and plans to expand their channel through both affiliation and ownership models highlight their commitment to growth. However, there may be some challenges in meeting operational efficiency and addressing potential share dilution as the company continues to invest in its operations and service its outstanding debt. Overall, we maintain our BUY rating and adjust our price target to $3.00 to account for a higher share count and potential risks, while considering the company's multi-billion-dollar market potential and favorable product positioning.
Bears say
Vivos Therapeutics is facing challenges in its transition from its VIP/dentist model to the sleep-center model, with lower revenue and higher expenses leading to a negative EPS estimate for FY26. However, the company's proprietary Vivos System offers a potential solution with limited treatment times and durable effects compared to the traditional CPAP treatment for sleep apnea, which affects over 30 million adults in the U.S. While there are risks to achieving its projected sales growth and price target, Vivos continues to work towards expanding its operations and gaining regulatory approvals, making it a potentially attractive long-term investment opportunity.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares